X0609 4 2026-08-05 0001682852 Moderna, Inc. MRNA 0001443340 Bancel Stephane false C/O MODERNA, INC. 325 BINNEY STREET CAMBRIDGE MA 02142 1 1 Chief Executive Officer 1 Common Stock 2026-08-05 4 M 0 499246 19.15 A 6687037 D Common Stock 2026-08-05 4 S 0 147473 56.21 D 6539564 D Common Stock 2026-08-05 4 S 0 124838 56.96 D 6414726 D Common Stock 2026-08-05 4 S 0 39891 58.12 D 6374835 D Common Stock 2026-08-05 4 S 0 187044 58.79 D 6187791 D Common Stock 2026-08-06 4 M 0 252469 19.15 A 6440260 D Common Stock 9210686 I See Footnote Common Stock 6564880 I See Footnote Stock Option (Right to Buy) 19.15 2026-08-05 4 M 0 370853 0 D 2026-08-10 Common Stock 370853 187541 D Stock Option (Right to Buy) 19.15 2026-08-05 4 M 0 128393 0 D 2026-08-10 Common Stock 128393 64928 D Stock Option (Right to Buy) 19.15 2026-08-06 4 M 0 187541 0 D 2026-08-10 Common Stock 187541 0 D Stock Option (Right to Buy) 19.15 2026-08-06 4 M 0 64928 0 D 2026-08-10 Common Stock 64928 0 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. This option is fully vested and exercisable. /s/ James Dillon, as Attorney-in-Fact 2026-08-07